Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Trial Profile

Post-Marketing Surveillance of Tofacitinib in Japanese Patients with Rheumatoid Arthritis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Oct 2018 Interim analysis results (data cut off date: 5 Nov 2017; n=3929) assessing incidence of serious infection events in patients with rheumatoid arthritis receiving tofacitinib, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 24 Oct 2018 Interim analysis results of safety data (data-cut off date: 5 Nov 2017 (6 month), n=3929) from this trial, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 16 Jun 2018 Results of 6- month interim analysis (n=3929 , data cut off: 5 Nov 2017) presented at the 19th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top